RE: stock shortage?5 Jul 2022 23:36
Mr India is having to battle with the compelling investment case of HEMO, particularly at this SP, and needing cash for other matters.
Junior pharma investment is tricky in the sense that you have to have conviction in the company and trust you will end up in the right place over time. Yet you still want to see short term positivity too.
There is no doubt that the big money is made on successful candidates which take time.
Eli say it takes on average 10 years from target to launch. I reckob we are miles ahead of that curve, especially with CAR T which has overtaken the previous primary candidate CDX.
Just to spice things up a bit CBR seems to have the sexy little profile that might draw sizeable investment pre-clinical.
Keep your investment time horizon realistic and the worlds your oyster. Demanding short term turnaround are very unlikely in any circumstances particular pre-clinical and even more so in a bear market.
I hold, try buy a few more when I can, and look forward to future updates. However long it takes!